Close menu


Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy

Myers, S M (2014) Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy. In: 26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics, 18-21 Nov 2014, Barcelona, Spain.

Item Type: Conference or Workshop Item (Poster)


Background: Extracellular signal-regulated kinase 5 (ERK5) is a member
of the protein kinase superfamily, which plays an essential role in the
transduction of extracellular signals to intracellular effectors. Activation of
the ERK5 signalling pathway is associated with cell survival, proliferation,
and differentiation, and thus ERK5 over-expression may have implications
in carcinogenesis. High levels of ERK5 are associated with poor patient
prognosis and the presence of bony metastases in advanced prostate
cancer. It has recently been discovered that ERK5 is also involved in
the development and progression of hepatocellular carcinoma (HCC).
Therefore, the discovery and development of small molecule inhibitors of
ERK5 is a desirable therapeutic area.
Method: Two potent inhibitors (1 and 2) have been described in the
literature and provide insight into the therapeutic effect caused by ERK5
inhibition and further guide our structure activity relationship (SAR) studies.
High throughput screening (HTS) of chemical libraries conducted by Cancer
Research Technology identified a number of hit compounds showing ERK5
inhibitory activity.
Results: Benzo[d]thiazole (3) and 3-cyanopyridine (4) based inhibitors
were identified and chosen for validation by re-synthesis. Interestingly, the
compounds showed good to moderate activity against ERK5.
Conclusion: ERK5 inhibition was achieved by two different chemotypes.
The syntheses of these small libraries and their biological evaluation will
be discussed.

[img] PDF (Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy)
Restricted to Repository staff only

Download (94kB) | Request a copy

More Information

Depositing User: Stephanie Myers


Item ID: 17742
Official URL:

Users with ORCIDS

Catalogue record

Date Deposited: 03 Jul 2024 10:55
Last Modified: 03 Jul 2024 11:00


Author: S M Myers
Author: Stephanie Myers

University Divisions

Faculty of Health Sciences and Wellbeing > School of Pharmacy and Pharmaceutical Sciences


Sciences > Chemistry
Sciences > Pharmacy and Pharmacology

Actions (login required)

View Item (Repository Staff Only) View Item (Repository Staff Only)